MARKETS
Earnings

Caribou Biosciences Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $1.499M Miss $2.279M Estimate

Aug 13, 2026 · 04:24 PM ET· updated 1h ago

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 25 percent. This is a 31.43 percent increase over losses of $(0.35) per share from

Share
Why It Matters

Caribou lost less money per share than people predicted, which is good—but they made way less money from selling things than expected, which is concerning. When a company loses money but is improving, watch if they can start making real sales soon.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.